§ GLP-1 & Weight Loss
Semaglutide
A GLP-1 receptor agonist used for type 2 diabetes (Ozempic, Rybelsus) and weight management (Wegovy).
Fact-checked 12 May 2026Plain-English Reference
Semaglutide is a once-weekly GLP-1 receptor agonist that slows gastric emptying, increases satiety, and improves glycemic control. It is sold under the brand names Ozempic (T2D), Rybelsus (oral T2D), and Wegovy (chronic weight management at the 2.4 mg dose). In the STEP 1 trial, Wegovy produced an average 14.9% body-weight reduction over 68 weeks.
§ Where Semaglutide Comes Up